Skip to main content

Advertisement

SpringerLink
Log in

Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin’s lymphoma

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Inflammatory cytokines play important roles in the pathogenesis of lymphomas and may reflect underlying biological processes including tumour–host interactions with prognostic information that is not afforded by conventional clinical parameters. Several lines of evidence suggest that serum levels of interleukin (IL)-6 and vascular endothelial growth factor (VEGF) are independent indicators of long-term outcome in non-Hodgkin’s lymphoma (NHL), but the clinical impact of early serial monitoring of these cytokines has not been reported. Serum samples from 64 newly diagnosed patients with aggressive NHL were obtained before the first cycle of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and then weekly until the second cycle was given. Serum IL-6 and VEGF were measured by commercial enzyme-linked immunosorbent assays (ELISA). Pre-treatment serum IL-6 and VEGF levels were significantly correlated to response rate and overall survival. A significant decrease of IL-6 and VEGF levels was observed in the first weeks after CHOP therapy in patients achieving a complete remission after treatment. Multivariate analysis indicated that early changes of IL-6 and VEGF serum levels within the first 3 weeks after initiation of chemotherapy were independent predictors of clinical response even when corrected for the influence of clinical prognostic factors. Only changes in serum IL-6 level had borderline significance for the prediction of overall survival. The data indicate that serial measurements of serum IL-6 and VEGF may be early prognostic indicators and support the hypothesis of a clinical impact by early recognition of poor-risk patients and candidates for new treatment options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jaffe ES, Harris NL, Vardiman JW, Stein H (2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization classification of tumours, IARC Press, Lyon, France

    Google Scholar 

  2. Armitage JO, Cheson BD (1988) Interpretation of clinical trials in diffuse large-cell lymphoma. J Clin Oncol 6:1335–1347

    Google Scholar 

  3. Cavalli F (1991) Treatment of lymphomas. Baillieres Clin Haematol 4:157–179

    Google Scholar 

  4. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 328:1002–1006

    Google Scholar 

  5. Cabanillas F, Velasquez WS, Mclaughlin P, Jagannath S, Hagemeister F, Redman JR, Swan F, Rodriguez MA (1988) Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin’s disease. Semin Hematol 25 [2 Suppl 2]:47–50

    Google Scholar 

  6. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP (1999) Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. J Clin Oncol 4:1244–1253

    Google Scholar 

  7. Ghia P, Caligaris-Cappio F (2000) The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. Adv Cancer Res 79:157–173

    Google Scholar 

  8. Levens JM, Gordon J, Gregory CD (2000) Micro-environmental factors in the survival of human B-lymphoma cells. Cell Death Differ 7:59–69

    Google Scholar 

  9. Voorzanger N, Toituou R, Garcia E, Delecluse HJ, Rousset F, Joab I, Favrot MC, Blay JY (1996) Interleukin (IL)-10 and IL-6 are produced in vivo in non-Hodgkin’s lymphoma cells and act as cooperative growth factors. Cancer Res 56:5499–5505

    Google Scholar 

  10. Ribatti D, Vacca A, Nico B, Fanelli M, Roncali L, Dammacco F (1996) Angiogenesis spectrum in the stroma of B-cell non-Hodgkin’s lymphomas: an immunohistochemical and ultrastructural study. Eur J Haematol 56:45–53

    Google Scholar 

  11. Salven P (2001) Angiogenesis in lymphoproliferative disorders. Acta Haematol 106:184–189

    Google Scholar 

  12. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 329:987–994

    Google Scholar 

  13. Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzock R (1995) Serum interleukin-6 levels correlate with prognosis in diffuse large cell lymphoma. J Clin Oncol 13:373–382

    Google Scholar 

  14. Fayad L, Cabanillas F, Talpaz M, McLaughlin P, Kurzrock R (1998) High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leuk Lymphoma 30:563–571

    Google Scholar 

  15. Yamamura M, Yamada Y, Momita S, Kamihira S, Tomonaga M (1998) Circulating interleukin-6 levels are elevated in adult T-cell leukaemia/lymphoma patients and correlate with adverse clinical features and survival. Br J Haematol 100:129–134

    Google Scholar 

  16. Salven P, Orpana A, Teerenhovi L, Joensuu H (2000) Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 96:3712–3718

    Google Scholar 

  17. Niitsu N, Okamato M, Nakamine H, Yoshino T, Tamaru J, Nakamura S, Higashihara M, Hirano M (2002) Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non-Hodgkin’s lymphoma. Eur J Haematol 68:91–100

    Google Scholar 

  18. Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F, Kurzrock R (1997) Clinical correlates of elevated serum levels of interleukin-6 in patients with untreated Hodgkin’s disease. Am J Med 102:21–28

    Google Scholar 

  19. Lissoni P, Rovelli F, Malugani F, Brivio F, Fumagalli L, Gardani GS (2003) Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer. Int J Biol Markers 18:152–155

    Google Scholar 

  20. Armitage J, Weisenburger D, Hutchins M, Moravec DF, Dowling M, Sorensen S, Mailliard J, Okerbloom J, Johnson PS, Howe D (1986) Chemotherapy for diffuse large-cell lymphoma: rapidly responding patients have more durable remissions. J Clin Oncol 4:160–164

    Google Scholar 

  21. Villela L, López-Guillermo A, Montoto S, Rives S, Bosch F, Perales M, Ferrer A, Esteve J, Colomo L, Campo E, Montserrat E (2001) Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer 91:1557–1562

    Google Scholar 

  22. Poon RT, Fan ST, Wong J (2001) Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 19:1207–1225

    Google Scholar 

  23. Berglund A, Molin D, Larsson A, Einarsson R, Glimelius B (2002) Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma. Ann Oncol 13:1430–1437

    Google Scholar 

  24. Hazar B, Paydas S, Zorludemir S, Sahin B, Tuncer I (2003) Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin’s lymphoma. Leuk Lymphoma 44:2089–2093

    Google Scholar 

  25. Salven P, Teerenhovi L, Joensuu H (1997) A high pre-treatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin’s lymphoma. Blood 90:3167–3172

    Google Scholar 

  26. Aydin F, Yilmaz M, Özdemir F, Kavgaci H, Yavuz MN, Yavuz AA (2002) Correlation of serum IL-2, IL-6 and IL-10 levels with international prognostic index in patients with aggressive non-Hodgkin’s lymphoma. Am J Clin Oncol 25:570–572

    Google Scholar 

  27. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242

    Google Scholar 

  28. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rube C, Loeffler M, German High-Grade Non-Hodgkin’s Lymphoma Study Group (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104:626–633

    Google Scholar 

  29. Bertz H, Zeiser R, Lange W, Fetscher S, Waller CF, Finke J (2004) Long-term follow-up after high-dose chemotherapy and autologous stem-cell transplantation for high-grade B-cell lymphoma suggests an improved outcome for high-risk patients with respect to the age-adjusted International Prognostic Index. Ann Oncol 15:1419–1424

    Google Scholar 

  30. Canellos GP (1988) Residual mass in lymphoma may not be residual disease. J Clin Oncol 6:931–933

    Google Scholar 

  31. Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, Vanuytsel L, Bormans G, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G (2001) Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin’s lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 19:414–419

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology and Clinical Research Unit, Herlev Hospital, University of Copenhagen, Herlev, Denmark

    Lars Møller Pedersen, Tobias Wirenfeldt Klausen, Ulla Høy Davidsen & Hans Erik Johnsen

  2. Department of Hematology, L Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, 2730, Herlev, Denmark

    Lars Møller Pedersen

Authors
  1. Lars Møller Pedersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tobias Wirenfeldt Klausen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ulla Høy Davidsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hans Erik Johnsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lars Møller Pedersen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pedersen, L.M., Klausen, T.W., Davidsen, U.H. et al. Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin’s lymphoma. Ann Hematol 84, 510–516 (2005). https://doi.org/10.1007/s00277-005-1020-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-005-1020-x

Keywords

Search

Navigation